Robert Schrepfer - ANI Pharmaceuticals Insider

ANI Pharmaceuticals Inc -- USA Stock  

USD 58.64  0.95  1.59%

VP of New Bus. Devel. and Contract Manufacturing

Mr. Robert W. Schrepfer is Vice President New Business Development and Contract Manufacturing of the Company. Mr. Schrepfer had served as the Companys Vice President of New Business Development and Contract Manufacturing and was promoted to Senior Vice President of New Business Development and Specialty Sales in May 2016. From 2005 to 2013, Mr. Schrepfer served as Assistant Portfolio Manager at Healthcare Value Capital, LLC, an SECregistered healthcare investment firm. Mr. Schrepfer comanaged the firms private equity portfolio and oversaw investments in healthcare services, devices and specialty pharmaceuticals. In addition, he was principal and founder of National Healthcare Analysis Group, LLC and served as Chief Financial Officer of National Healthcare Analysis Partners 1, LP, a partnership that seeks to identify and pursue healthcare fraud.
Age: 44  VP Since 2013  MBA    
Schrepfer is a Member of the Health Sector Advisory Council at Duke University where he earned his MBA in Finance and Health Sector Management.

Robert Schrepfer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.74 % which means that it generated profit of $6.74 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (0.63) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 201.51 M in liabilities with Debt to Equity (D/E) ratio of 115.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals Inc has Current Ratio of 3.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 2 records

VP Since

Naamit SherVascular Biogenics Ltd
Marc KirchmeierVBI Vaccines Inc

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people.ANI Pharmaceuticals Inc (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Search Now

Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
Hide  View All  NextLaunch Equity Search

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ANI Pharmaceuticals Inc to your portfolio

Top Management

ANI Pharmaceuticals Inc Leadership Team
Robert Brown, Chairman, MBA
Charlotte Arnold, President, MBA
Mark Ginski, President, Ph.D
Robert Schrepfer, VP, MBA
Daniel Raynor, Director
Stephen Carey, President
David Sullivan, VP, Ph.D
Karen Quinn, President
James Marken, VP
Peter Lankau, Director
Fred Holubow, Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO
Thomas Penn, Director

Stock Performance

ANI Pharmaceuticals Performance Indicators